Clinical Trials Logo
  1. Home
  2. AIDS-related Lymphoma
  3. NCT03690895

Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy — LCPVIH  

Central Nervous System Lymphoma Clinical Trial

Official title:
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

Clinical Trial Summary

This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03690895
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact
Status Completed
Phase
Start date March 15, 2015
Completion date October 1, 2016
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516655 - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients Phase 2
Recruiting NCT05054426 - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL Phase 3
Recruiting NCT02623010 - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Phase 2
Recruiting NCT04548648 - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas Phase 2
Active, not recruiting NCT00293475 - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 1/Phase 2
Completed NCT03342586 - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated NCT02420795 - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1/Phase 2
Completed NCT01011920 - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00967200 - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors N/A
Recruiting NCT03684980 - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Early Phase 1
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2
Recruiting NCT04938297 - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma Phase 2
Recruiting NCT04792489 - DALY II USA/ MB-CART2019.1 for DLBCL Phase 2
Completed NCT01458730 - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Phase 2
Completed NCT00153530 - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Phase 4
Recruiting NCT04186520 - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT05816746 - Decitabine and Anti-PD-1 in R/R DLBCL Phase 2
Recruiting NCT06031194 - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting NCT03962127 - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Recruiting NCT05114330 - Secondary Central Nervous System Lymphoma Registry - Charité